MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Condition:   Follicular Lymphoma and Marginal Zone Lymphoma Interventions:   Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection;   Drug: Lenalidomide Sponsor:   Beijing Mabworks Biotech Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials